OneMedNet Delivers a Real-World Data feed of 1.5M Patients consisting of 4M encounters
Rhea-AI Summary
OneMedNet (Nasdaq: ONMD) delivered an anonymized Real-World Data feed covering 1.5 million patients and 4 million encounters to a healthcare data and analytics organization on January 2026. The multimodal dataset exceeds 1.49 billion datapoints and includes longitudinal clinical domains such as practitioner notes, immunizations, conditions, medications, encounters, and observations. Delivered under OneMedNet’s subscription model and powered by Palantir AIP Foundry, the feed supported enterprise-scale testing, validation, and demonstrated ingestion, harmonization, and operationalization of complex healthcare data, positioning the company to scale subscription-based RWD delivery and pursue additional customers.
Positive
- 1.5M patients dataset delivered
- 4M encounters included in the feed
- Dataset exceeds 1.49 billion datapoints
- Multimodal longitudinal clinical domains (notes, meds, observations)
- Delivered under a subscription model enabling recurring access
Negative
- None.
News Market Reaction
On the day this news was published, ONMD gained 5.89%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.0% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $53M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ONMD fell 22.73% while peers were mixed: ZCMD down 16.38%, MGRX down 7.7%, BEAT modestly lower, STRM flat, and HCTI up 1.88%. The magnitude of ONMD’s move diverges from generally smaller peer moves.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 22 | Shareholder letter | Positive | +6.9% | CEO letter detailing 2025 progress and 2026 strategic plans. |
| Dec 10 | Conference update | Positive | -4.8% | Reported strong RSNA engagement and traction for Palantir-powered iRWD platform. |
| Nov 24 | Product showcase | Positive | -1.5% | Announced redesigned data exploration and cohort-building platform for RSNA 2025. |
| Nov 20 | Network expansion | Positive | -10.7% | Disclosed major iRWD network expansion in sites, patients, and clinical exams. |
| Nov 17 | Earnings / bookings | Positive | -3.6% | Q3 results with 815% bookings increase and higher inbound demand. |
Recent history shows mostly negative price reactions to operationally positive updates, with four divergences and only one aligned positive move.
Over the past six months, ONMD has highlighted expanding its iRWD network, strong bookings growth, and adoption of Palantir-powered platforms. Updates on RSNA 2025, a redesigned cohort-building platform, and substantial network expansion to >47 million patient records and >186 million clinical exams were followed mostly by share-price declines. A shareholder letter citing a $19.6M liability reduction drew a positive reaction. Today’s large-scale data-feed milestone fits the ongoing push toward subscription-based, recurring RWD revenue.
Market Pulse Summary
The stock moved +5.9% in the session following this news. A strong positive reaction aligns with the company’s focus on scaling its regulatory-grade Real-World Data platform but would contrast with prior patterns where four of the last five upbeat announcements saw negative price moves. Investors might question sustainability given Q3 2025 results that included a $6.59M operating loss and going-concern language, so any sharp upside move could be sensitive to follow‑through on recurring subscription revenues.
Key Terms
real-world data medical
real-world evidence medical
multimodal technical
de-identified medical
AI-generated analysis. Not financial advice.
MINNEAPOLIS, Jan. 16, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced that this month it has successfully delivered an anonymized Real-World Data feed representing 1.5 million patients and 4 million encounters to a premier healthcare data and analytics organization serving top pharmaceutical, biotechnology, and medical device companies. The data feed, which was delivered under OneMedNet’s subscription model, supports enterprise-scale testing and validation of the recipient’s platform, confirming its ability to ingest, harmonize, and operationalize complex, multimodal healthcare data – an important step toward its production deployment and commercial scale.
The de-identified feed, exceeding 1.49 billion datapoints of structured and unstructured data, covers extensive longitudinal clinical domains. Integrating full patient journeys – including practitioner notes, immunizations, conditions, medications, encounters, and observations – this multimodal dataset delivers the clinical fidelity required for advanced analytics, regulatory grade research, and AI applications. The delivery enabled full enterprise-scale testing and validation of the recipient’s platform, confirming seamless ingestion, harmonization, and operationalization of complex healthcare data and clearing the path to production deployment and commercial scale.
OneMedNet believes this milestone further validates its subscription model, which provides recurring, on-demand access to continuously refreshed RWD via standardized schemas, scalable delivery protocols, driven by AI automation. By transitioning customers from one-time transactions to predictable annual recurring revenue (ARR) streams aligned with platform adoption and production workflows, OneMedNet would be building durable, high-value partnerships that enhance retention, accelerate monetization, and support long-term shareholder value.
“Life sciences and data platform partners require Real-World Data at scale and sufficiently rich to capture real clinical complexity,” said Aaron Green, CEO and President of OneMedNet. “Delivering a 1.5M patient, multimodal dataset under our subscription model demonstrates our ability to support enterprise validation today while advancing subscription-based data feeds that create durable, long-term value, advancing our strategy to create satisfied subscription customers providing recurring revenue in the healthcare data market.”
Powered by Palantir AIP Foundry, OneMedNet’s platform enables data aggregators, life sciences organizations, and technology partners to reduce integration risk, shorten time-to-market, and scale commercialization of Real-World Evidence (RWE). With this validation complete and additional customers in the pipeline, OneMedNet believes it is well-positioned to expand its healthcare data ecosystem.
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our products, plans and strategies, and our ability to achieve our operational strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION
FAQ
What did OneMedNet (ONMD) deliver on January 16, 2026?
How large is the OneMedNet dataset and what data types does ONMD include?
Was the OneMedNet data delivery a one-time sale or subscription for ONMD?
Which platform powered OneMedNet’s data delivery for ONMD’s feed?
What did the enterprise-scale validation accomplish for OneMedNet (ONMD)?
